Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.34 |
| ▸ | CCR3 | P51677 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.32 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2116580 | 0.86 | GNAO1 (0.40) | SIGMAR1GNAO1KCNH2HRH3 | |
| SCHEMBL2116260 | 0.80 | GNAI3 (0.39) | GNAO1KCNH2GNAI3GNAI1HRH3 | |
| SCHEMBL4417561 | 0.79 | NCF1 (0.50) | SIGMAR1GNAO1CCR3GNAI3GNAI1 | |
| SCHEMBL2118494 | 0.79 | CHRM2 (0.36) | SIGMAR1GNAO1CCR3HRH3 | |
| SCHEMBL2116403 | 0.79 | GNAO1 (0.41) | SIGMAR1GNAO1CCR3KCNH2GNAI3 | |
| SCHEMBL3424493 | 0.79 | HRH3 (0.42) | SIGMAR1GNAO1CCR3KCNH2SLC6A4 | |
| SCHEMBL2119095 | 0.79 | SIGMAR1 (0.33) | SIGMAR1GNAO1 | |
| SCHEMBL5271415 | 0.77 | BCHE (0.36) | — | |
| SCHEMBL3424280 | 0.76 | ACHE (0.45) | GNAO1KCNH2SLC6A2SLC6A4HRH3 | |
| SCHEMBL2116456 | 0.74 | CARM1 (0.52) | SIGMAR1KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158652-B2 | 1-Difluoromethyl-5-{4-[3-(1-piperidinyl)propoxy]phenyl}-2(1H)-pyridone; compounds act as histamine-H3 receptor antagonistic substances or inverse-agonistic substances; useful as preventives or remedies for various circular system diseases, nervous system diseases, metabolic system diseases | MSD K.K. (JP) | 2012-04-17 | — | — | US | disclosed |
| US-20080269287-A1 | Substituted Pyridone Derivative | MSD K.K. (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1820797-A1 | SUBSTITUTED PYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269287-A1 | Substituted Pyridone Derivative | HRH3, HRH4, HRH1 | SIGMAR1 86/4885GNAO1 2673/4885CCR3 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.